TQB2102 not checked

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
13 active
14 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.”In the company’s words, NCT06561607 on ClinicalTrials.gov
Tested for
Breast Cancer (4 trials), HER2 IHC3+ Advanced Colorectal Cancer, HER2-positive Breast Cancer, Metastatic Breast Cancer, Gynecological Tumors, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma, Biliary Tract Cancer and 2 more
Main trialPhase 3
“The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1…”In the company’s words, NCT06561607 on ClinicalTrials.gov

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jan 2027 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Phase 3Not yet recruiting Aug 2027 A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Phase 3Recruiting Sep 2027 A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3Recruiting Mar 2028 Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Phase 3Recruiting Jul 2029 A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Phase 2Active, not recruiting 8 May 2025 A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 2Recruiting May 2026 A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
Phase 2Recruiting Jun 2026 A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Phase 2Recruiting Jun 2026 The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Phase 2Recruiting Sep 2026 A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
Phase 1/2Recruiting May 2027 A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/2Recruiting Mar 2028 Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase 1Active, not recruiting 21 Jul 2025 Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Phase 1Completed 1 Feb 2025 A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB2102

Following is part of Solo: you see every change to TQB2102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in